Molecular Basis of CYP19A1 Deficiency in a 46,XX Patient With R550W Mutation in POR: Expanding the PORD Phenotype
- 15 February 2020
- journal article
- research article
- Published by The Endocrine Society in Journal of Clinical Endocrinology & Metabolism
- Vol. 105 (4), e1272-e1290
- https://doi.org/10.1210/clinem/dgaa076
Abstract
Context Mutations in Cytochrome P450 oxidoreductase (POR) cause a form of congenital adrenal hyperplasia (CAH). We are reporting a novel R550W mutation in POR identified in a 46, XX patient with signs of aromatase deficiency. Objective Analysis of aromatase deficiency from R550W mutation in POR. Design, setting, and patient Both the child and the mother had signs of virilization. Ultrasound revealed the presence of uterus and ovaries. No defects in CYP19A1 were found, but further analysis with a targeted Disorders of Sexual Development NGS panel (DSDSeq.V1, 111 genes) on a NextSeq (Illumina) platform in Madrid and Barcelona, Spain, revealed compound heterozygous mutations c.73_74delCT/p.L25FfsTer93 and c.1648C>T/p.R550W in POR. WT and R550W POR were produced as recombinant proteins and tested with multiple cytochrome P450 enzymes at University Children’s Hospital, Bern, Switzerland. Main outcome measure and Results R550W POR showed 41% of the WT activity in cytochrome c and 7.7% activity for reduction of MTT. Assays of CYP19A1 showed a severe loss of activity and CYP17A1, as well as CYP21A2 activities, were also lost by more than 95%. Loss of CYP2C9, CYP2C19, and CYP3A4 activities was observed for the R550W-POR. Predicted adverse effect on aromatase activity as well as a reduction in binding of NADPH was confirmed. Conclusions Pathological effects due to POR R550W were identified, expanding the knowledge of molecular pathways associated with aromatase deficiency. Screening of the POR gene may provide a diagnosis in CAH without defects in genes for steroid metabolizing enzymes.Keywords
Other Versions
Funding Information
- Swiss National Science Foundation (31003A-134926)
- Novartis Foundation for Medical-biological Research (18A053)
- Fondo de Investigación Sanitaria (PI05/01647)
This publication has 70 references indexed in Scilit:
- Pharmacogenomics of Cytochrome P450 3A4: Recent Progress Toward the “Missing Heritability” ProblemFrontiers in Genetics, 2013
- Genotype-Phenotype Analysis in Congenital Adrenal Hyperplasia due to P450 Oxidoreductase DeficiencyJournal of Clinical Endocrinology & Metabolism, 2012
- Tissue physiology and pathology of aromataseSteroids, 2012
- Why Boys Will Be Boys: Two Pathways of Fetal Testicular Androgen Biosynthesis Are Needed for Male Sexual DifferentiationAmerican Journal of Human Genetics, 2011
- Substrate-specific modulation of CYP3A4 activity by genetic variants of cytochrome P450 oxidoreductasePharmacogenetics and Genomics, 2010
- Altered heme catabolism by heme oxygenase-1 caused by mutations in human NADPH cytochrome P450 reductaseBiochemical and Biophysical Research Communications, 2010
- Clinical, Genetic, and Enzymatic Characterization of P450 Oxidoreductase Deficiency in Four PatientsJournal of Clinical Endocrinology & Metabolism, 2009
- Human Cytochrome P450 Oxidoreductase Deficiency Caused by the Y181D Mutation: Molecular Consequences and Rescue of DefectDrug Metabolism and Disposition, 2009
- Genetics of P450 oxidoreductase: Sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutationsProceedings of the National Academy of Sciences of the United States of America, 2008
- Variable Phenotypes Associated with Aromatase (CYP19) Insufficiency in HumansJournal of Clinical Endocrinology & Metabolism, 2007